J. Safra Sarasin Holding’s Aurinia Pharmaceuticals AUPH Stock Holding History

J. Safra Sarasin Holding’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$378K	Hold	25,500	–	–	0.01%	598
2026 Q1	$378K	Hold	25,500	–	–	0.01%	437
2025 Q4	$407K	Hold	25,500	–	–	0.01%	417
2025 Q3	$282K	Hold	25,500	–	–	﹤0.01%	444
2025 Q2	$216K	Hold	25,500	–	–	﹤0.01%	477
2025 Q1	$205K	Hold	25,500	–	–	﹤0.01%	473
2024 Q4	$229K	Hold	25,500	–	–	﹤0.01%	451
2024 Q3	$187K	Hold	25,500	–	–	﹤0.01%	434
2024 Q2	$146K	Buy	+25,500	New	+$134K	﹤0.01%	452

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Safra Sarasin Holding's AUPH Position: Q2 2026 in Review

J. Safra Sarasin Holding held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 25,500 shares worth $378K. The position accounts for 0.01% of the portfolio, ranked #598.

J. Safra Sarasin Holding first reported a position in AUPH in Q2 2024 and has held it in 9 quarters since. The position peaked at $407K in Q4 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

J. Safra Sarasin Holding held 25,500 shares of Aurinia Pharmaceuticals worth $378K as of Q2 2026.
J. Safra Sarasin Holding left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
Aurinia Pharmaceuticals made up 0.01% of J. Safra Sarasin Holding's portfolio in Q2 2026, its #598 holding.
J. Safra Sarasin Holding first reported a position in Aurinia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
J. Safra Sarasin Holding's Aurinia Pharmaceuticals position peaked at $407K in Q4 2025.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on J. Safra Sarasin Holding's 13F filing for Q2 2026, filed 31 Jul 2026.